Amyloid-β Antibody Treatment Leads to Rapid Normalization of Plaque-Induced Neuritic Alterations

Journal of Neuroscience

Volumn 23, Issue 34, 2003, Pages 10879-10883

  Lombardo, Julianne A ^a   Stern, Edward A ^a   McLellan, Megan E ^a   Kajdasz, Stephen T ^a   Hickey, Gregory A ^a   Bacskai, Brian J ^a   Hyman, Bradley T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer; Amyloid; Antibody; Immunotherapy; Neurodegeneration; Plasticity

Indexed keywords

AMYLOID BETA ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; CELL SWELLING; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; IMMUNOPHARMACOLOGY; IMMUNOTHERAPY; MOUSE; NERVE CELL; NERVE CELL LESION; NERVE CELL PLASTICITY; NEUROPATHOLOGY; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; SENILE PLAQUE; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

EID: 0344629707     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-34-10879.2003     Document Type: Article

References (20)

1. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT (2001) Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7:369-372.
2. Bacskai BI, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 22:7873-7878.
3. Campbell MJ, Morrison JH (1989) Monoclonal antibody to neurofilament protein (SMI-32) labels a subpopulation of pyramidal neurons in the human and monkey neocortex. J Comp Neurol 282:191-205.
4. D'Amore JD, Kajdasz ST, McLellan ME, Bacskai BJ, Stern EA, Hyman BT (2003) In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J Neuropathol Exp Neurol 62:137-145.
5. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagoplan S, Johnson-Wood K, Kahn K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523-527.
6. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer M, Umbricht D, deq Uervain D, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch R (2003) Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38:547-554.
7. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
8. Hyman BT, Tanzi RE, Marzloff K, Barbour R, Schenk D (1992) Kunitz protease inhibitor-containing amyloid beta protein precursor immunoreactivity in Alzheimer's disease. J Neuropathol Exp Neurol 51:76-83.
9. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT (1997) Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 17:7053-7059.
10. Joachim C, Games D, Morris J, Ward P, Frenkel D, Selkoe D (1991) Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques. Am J Pathol 138:373-384.
11. Knowles RB, Gomez-Isla T, Hyman BT (1998) Abeta associated neuropil changes: correlation with neuronal loss and dementia. J Neuropathol Exp Neurol 57:1122-1130.
12. Knowles RB, Wyart C, Buldyrev SV, Cruz L, Urbanc B, Hasselmo ME, Stanley HE, Hyman BT (1999) Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc Natl Acad Sci USA 96:5274-5279.
13. Le R, Cruz L, Urbanc B, Knowles RB, Hsiao-Ashe K, Duff K, Irizarry MC, Stanley HE, Hyman BT (2001) Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption. J Neuropathol Exp Neurol 60:753-758.
14. Masliah E, Sisk A, Mallory M, Games D (2001) Neurofibrillary pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. J Neuropathol Exp Neurol 60:357-368.
15. Mesulam MM (2000) A plasticity-based theory of the pathogenesis of Alzheimer's disease. Ann NY Acad Sci 924:42-52.
16. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9:448-452.
17. Schwab C, Steele JC, McGeer PL (1997) Dystrophic neurites are associated with early stage extracellular neurofibrillary tangles in the parkinsonism-dementia complex of Guam. Acta Neuropathologica 94:486-492.
18. Selkoe DJ (1996) Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 271:18295-18298.
19. Stepanyants A, Hof PR, Chklovskii DB (2002) Geometry and structural plasticity of synaptic connectivity. Neuron 34:275-288.
20. Trachtenberg JT, Chen BE, Knott GW, Feng G, Sanes JR, Welker E, Svoboda K (2002) Long-term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. Nature 420:788-794.